PHC Holdings Corporation
6523.TMEDIUMScore: 53.7Tactical · Weight: 5%· Data as of 2026-04-17
Investment Thesis
Deep-value turnaround. PB 0.85x (below book), 3.92% div yield, FCF ¥32B on ¥135B mcap = 23.6% FCF yield. StockAnalysis Forward PE 10.71x implies consensus expects 3.6x EPS recovery from trailing PE 38.5x. Portfolio: Ascensia (diabetes BGM from Bayer 2016), Medicom EMR (Japan), Epredia (cancer pathology from Thermo Fisher 2019), LSBT (cell culture). All benefit from aging + chronic disease. Former Panasonic Healthcare, KKR/Mitsui PE-backed.
Risk
1) Net margin 0.97% — razor-thin, one bad quarter = loss. 2) D/E 2.48x — LBO-era leverage slow to unwind. 3) KKR/Mitsui overhang — PE sponsors tend to exit into strength. 4) CGM adoption (Dexcom G7, Abbott Libre 3) is a secular threat to Ascensia BGM. 5) Revenue flat (-0.05% YoY), EPS -40% YoY — turnaround not yet proven.
Monitoring Trigger
If FY2026 full-year OpMar exceeds 8% (up from 6.23%), ADD to 8%. If KKR/Mitsui block sale or secondary offering, WATCH and re-enter post-placement. If OpMar drops below 5% or NI goes negative, EXIT.
Key Dates
Key Metrics
Business Segments
| Segment | Revenue | Share | Description |
|---|---|---|---|
| Diabetes Care (Ascensia) | |||
| Healthcare Solutions (Medicom) | |||
| Diagnostics (Epredia) | |||
| Life Sciences (LSBT) |
Supply Chain Evidence
| Evidence | Customer | Product | Detail |
|---|---|---|---|
| confirmed | Japanese + global pharmacies/retailers | Ascensia CONTOUR BGM + test strips | #3 global BGM franchise |
| confirmed | Japanese hospitals + clinics | Medicom EMR and dispensing | Domestic EMR platform |
| confirmed | Global pathology labs | Epredia reagents + slides | Acquired from Thermo Fisher 2019 |
| confirmed | CGM vs BGM | Secular CGM threat to Ascensia BGM | |
| confirmed | Equity overhang | KKR acquired Panasonic Healthcare 2014; Mitsui joined 2016; IPO Oct 2021 |